放射性粒子植入联合靶向药物治疗NSCLC的疗效及对TSGF等指标和预后的影响

Efficacy of Radioactive Particle Implantation Combined with Targeted Drugs in the Treatment of NSCLC and the Effect on TSGF and Other Indicators and Prognosis

目的探讨放射性粒子植入联合靶向药物治疗NSCLC的疗效及对TSGF等指标和预后的影响。方法回顾性选取96例晚期NSCLC(均为EGFR阳性)的患者,根据治疗方式分为2组。研究组患者52例,采用靶向药物联合^(125)I粒子植入术治疗,而对照组患者44例,则采用单纯靶向药物治疗,比较2组患者的临床疗效等差异。结果研究组的治疗总有效率(78.9%)显著高于对照组(56.8%)(P<0.05);2组治疗后不良反应发生情况比较无差异(P>0.05)。治疗前2组的肿瘤相关指标比较无差异(P>0.05),而治疗后2组的肿瘤相关指标均较治疗前降低,且研究组降低更为显著(P<0.05)。治疗后1年,研究组的预后情况优于对照组(P<0.05)。结论^(125)I粒子植入术联合靶向药物对NSCLC的疗效较佳,且不增加不良反应发生率,同时可显著降低肿瘤标志物水平,改善预后,值得临床推广应用。

Objective To investigate the efficacy of radioactive particle implantation combined with targeted drugs in the treatment of NSCLC and the effect on TSGF and other indicators and prognosis.Methods Retrospective analysis of 96 patients with advanced NSCLC(all EGFR-positive)were divided into 2 groups according to treatment modality.Among them,52 patients in the study group were treated with targeted drugs combined with ^(125)I particle implantation,while 44 patients in the control group were treated with targeted drugs alone,compared the clinical efficacy and other differences between the 2 groups.Results The overall effective rate of the study group(78.9%)was significantly higher than that of the control group(56.8%)after surgery(P<0.05);There was no difference in the occurrence of adverse reactions between the 2 groups after treatment(P>0.05);There was no difference in the tumor-related indexes between the 2 groups before treatment(P>0.05),while the tumor-related indexes in both groups decreased after treatment compared with those before treatment,and the decrease was more significant in the study group(P<0.05).One year after treatment,the prognosis of the study group was better than that of the control group(P>0.05).Conclusion ^(125)I particle implantation combined with targeted drugs has better efficacy in NSCLC without increasing the incidence of adverse reactions,while significantly reducing tumor marker levels and improving prognosis,which is worthy of clinical promotion and application.